Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jordan Cammarota"'
Autor:
Peter Hur, Kathleen G. Lomax, Raluca Ionescu-Ittu, Ameur M. Manceur, Jipan Xie, Jordan Cammarota, Raju Gautam, Navneet Sanghera, Nina Kim, Alexei A. Grom
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-13 (2021)
Abstract Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed
Externí odkaz:
https://doaj.org/article/895a29c829b840f387ab20d693d70cfe
Autor:
Peter Hur, Esther Yi, Raluca Ionescu-Ittu, Ameur M. Manceur, Kathleen G. Lomax, Jordan Cammarota, Jipan Xie, Raju Gautam, Priscila Nakasato, Navneet Sanghera, Nina Kim, Alexei A. Grom
Publikováno v:
Rheumatology and therapy. 9(1)
The aim of this study was to understand the reasons for canakinumab initiation among patients with Still's disease, including systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD), in US clinical practice.Physicians ret
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::223825486b8cca37384b227279bd3a55
https://pubmed.ncbi.nlm.nih.gov/34874547
https://pubmed.ncbi.nlm.nih.gov/34874547
Autor:
Jipan Xie, Nina Kim, Kathleen G Lomax, Peter Hur, Raju Gautam, Jordan Cammarota, Raluca Ionescu-Ittu, Navneet Sanghera, Ameur M. Manceur, Alexei A. Grom
Publikováno v:
Pediatric Rheumatology Online Journal
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-13 (2021)
Pediatric Rheumatology Online Journal, Vol 19, Iss 1, Pp 1-13 (2021)
Background Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed to chara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c66b7e81c636b5f95639c2e94acf5ea
http://europepmc.org/articles/PMC8439059
http://europepmc.org/articles/PMC8439059
Publikováno v:
Journal of Medical Economics. 23:80-85
Aims: Adalimumab, infliximab, and ustekinumab have been approved for patients with moderate-to-severe Crohn’s disease in Japan. This study compared the relative efficacy and cost-effectiveness of a...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a10cc374a507c415aaf00ce68ae2cc5c
https://doi.org/10.1080/13696998.2019.1642900
https://doi.org/10.1080/13696998.2019.1642900
Autor:
Alan Friedman, Ruta Sawant, Patrick Tang, Vishvas Garg, Christopher J Edwards, Ella X Du, Keith A. Betts, Jordan Cammarota
Publikováno v:
Rheumatology. 59
Background Upadacitinib (UPA), a JAK1 selective inhibitor, is being investigated as monotherapy and combination therapy with DMARDs for the treatment of moderate-to-severe RA. To date, no head-to-head trials have compared the effectiveness of UPA wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af1f3aa16abafba5457b95c16c2f1af
https://doi.org/10.1093/rheumatology/keaa111.219
https://doi.org/10.1093/rheumatology/keaa111.219
Autor:
Vishvas Garg, Ella Du, Keith A. Betts, Jordan Cammarota, Alan Friedman, Ruta Sawant, Christopher J Edwards, Patrick Tang
Publikováno v:
Poster Presentations.
Background Upadacitinib (UPA), a JAK1 selective inhibitor, is being investigated as monotherapy and combination therapy with DMARDs for the treatment of moderate-to-severe RA. To date, no head-to-head trials have compared the effectiveness of UPA wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3644be5e06e7c1f82bd49f934116e41e
https://doi.org/10.1136/annrheumdis-2019-eular.7189
https://doi.org/10.1136/annrheumdis-2019-eular.7189